Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
downgraded at Goldman from Neutral to Sell. Stock is up 44% year-to-date and the company is facing increased competition. $20 price target.
downgraded at Argus from Buy to Hold. Company is seeing lower sales.
downgraded at BofA/Merrill from Buy to Underperform. Company is facing growth headwinds. $44 price target.
rated new Buy at Goldman Sachs. $50 price target. Provenge is a potential blockbuster drug.
upgraded at BofA/Merrill to Buy. Gainful employment regulation was softened. $68 price target.
upgraded at BofA/Merrill from Underperform to Neutral, Bank of America/Merrill Lynch said. $24 price target. DOE has lessened its regulations on the for-profit group.
rated new Buy at Brean Murray. $26 price target. Company can continue to expand margins, despite rising input costs.
downgraded at UBS from Buy to Neutral. Valuation call, based on a $41 price target.
upgraded at UBS from Neutral to Buy. $62 price target. Company can deliver above-consensus growth over the next several quarters.
rated new Buy at Brean Murray. $174 price target. Company is a market leader in what should become a top hepatitis C therapy.
End of report.
This article was written by a staff member of TheStreet.